Increased factor VIII activity and dural sinus thrombosis.
Celkan
Tiraje
T
Ozkan
Alp
A
Apak
Hilmi
H
Kuruoglu
Sebuh
S
Yuksel
Lebriz
L
Yildiz
Inci
I
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005169:Factor VIII / Q000378:metabolism*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011859:Radiography; D012307:Risk Factors; D020225:Sagittal Sinus Thrombosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D005169:Factor VIII; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin